Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Use of Alpha-linolenic (ALA), Docosahexaenoic (DHA) and Eicosapanthene (EPA) Esters in the Prevention of Cardiovascular Diseases in Adults.

NCT04743050 is registered in ClinicalTrials.gov with Wroclaw Medical University as lead sponsor.

NCT NCT04743050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04743050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Use of Alpha-linolenic (ALA), Docosahexaenoic (DHA) and Eicosapanthene (EPA) Esters in the Prevention of Cardiovascular Diseases in Adults.
Lead sponsor
Wroclaw Medical University
Phase
Phase 3
Overall status
Unknown status
Start date
December 9, 2020
Completion date
June 30, 2022
Enrollment
200 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

alpha-linolenic acid, anti-inflammatory agents, cardiovascular diseases, docosahexaenoic acids, eicosapentaenoic acid, fatty acids, preventive health services, preventive medicine